These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

637 related articles for article (PubMed ID: 27703341)

  • 1. Cost-effectiveness and budget impact of the fixed-dose dual bronchodilator combination tiotropium-olodaterol for patients with COPD in the Netherlands.
    van Boven JF; Kocks JW; Postma MJ
    Int J Chron Obstruct Pulmon Dis; 2016; 11():2191-2201. PubMed ID: 27703341
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of an enhanced health-economic model and cost-effectiveness analysis of tiotropium + olodaterol Respimat® fixed-dose combination for chronic obstructive pulmonary disease patients in Italy.
    Selya-Hammer C; Gonzalez-Rojas Guix N; Baldwin M; Ternouth A; Miravitlles M; Rutten-van Mölken M; Goosens LM; Buyukkaramikli N; Acciai V
    Ther Adv Respir Dis; 2016 Oct; 10(5):391-401. PubMed ID: 27405723
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term cost-effectiveness of the fixed-dose combination of tiotropium plus olodaterol based on the DYNAGITO trial results.
    Hoogendoorn M; Corro Ramos I; Baldwin M; Luciani L; Fabron C; Detournay B; Rutten-van Mölken MPMH
    Int J Chron Obstruct Pulmon Dis; 2019; 14():447-456. PubMed ID: 30863045
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of tiotropium + olodaterol maintenance treatment in patients with COPD in the TONADO
    Ferguson GT; Karpel JP; Clerisme-Beaty E; Grönke L; Voß F; Buhl R
    Int J Chron Obstruct Pulmon Dis; 2016; 11():2701-2710. PubMed ID: 27843306
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of the fixed-dose combination tiotropium/olodaterol versus tiotropium monotherapy or a fixed-dose combination of long-acting β2-agonist/inhaled corticosteroid for COPD in Finland, Sweden and the Netherlands: a model-based study.
    Hoogendoorn M; Corro Ramos I; Soulard S; Cook J; Soini E; Paulsson E; Rutten-van Mölken M
    BMJ Open; 2021 Aug; 11(8):e049675. PubMed ID: 34348953
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined bronchodilators (tiotropium plus olodaterol) for patients with chronic obstructive pulmonary disease.
    Ramadan WH; Kabbara WK; El Khoury GM; Al Assir SA
    Int J Chron Obstruct Pulmon Dis; 2015; 10():2347-56. PubMed ID: 26586940
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of tiotropium + olodaterol versus tiotropium or placebo by COPD disease severity and previous treatment history in the OTEMTO® studies.
    Singh D; Gaga M; Schmidt O; Bjermer L; Grönke L; Voß F; Ferguson GT
    Respir Res; 2016 Jun; 17(1):73. PubMed ID: 27316465
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lung function and long-term safety of tiotropium/olodaterol in East Asian patients with chronic obstructive pulmonary disease.
    Bai C; Ichinose M; Lee SH; Lee KH; Jöns O; Bothner U; Zhao Y; Buhl R
    Int J Chron Obstruct Pulmon Dis; 2017; 12():3329-3339. PubMed ID: 29200840
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of baseline symptom burden on treatment response in COPD.
    Martinez FJ; Abrahams RA; Ferguson GT; Bjermer L; Grönke L; Voß F; Singh D
    Int J Chron Obstruct Pulmon Dis; 2019; 14():181-194. PubMed ID: 30655665
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Probabilistic Markov model to assess the cost-effectiveness of bronchodilator therapy in COPD patients in different countries.
    Oostenbrink JB; Rutten-van Mölken MP; Monz BU; FitzGerald JM
    Value Health; 2005; 8(1):32-46. PubMed ID: 15841892
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness analysis of umeclidinium/vilanterol for the management of patients with moderate to very severe COPD using an economic model.
    Wilson MR; Patel JG; Coleman A; McDade CL; Stanford RH; Earnshaw SR
    Int J Chron Obstruct Pulmon Dis; 2017; 12():997-1008. PubMed ID: 28392684
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness analysis of a fixed-dose combination of indacaterol and glycopyrronium as maintenance treatment for COPD.
    Chan MC; Tan EC; Yang MC
    Int J Chron Obstruct Pulmon Dis; 2018; 13():1079-1088. PubMed ID: 29670344
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The 24-h lung-function profile of once-daily tiotropium and olodaterol fixed-dose combination in chronic obstructive pulmonary disease.
    Beeh KM; Westerman J; Kirsten AM; Hébert J; Grönke L; Hamilton A; Tetzlaff K; Derom E
    Pulm Pharmacol Ther; 2015 Jun; 32():53-9. PubMed ID: 25956072
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Benefits of Tiotropium/Olodaterol Compared with Tiotropium in Patients with COPD Receiving only LAMA at Baseline: Pooled Analysis of the TONADO
    Buhl R; Singh D; de la Hoz A; Xue W; Ferguson GT
    Adv Ther; 2020 Aug; 37(8):3485-3499. PubMed ID: 32462607
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of tiotropium/olodaterol on lung volume, exercise capacity, and physical activity.
    Ichinose M; Minakata Y; Motegi T; Ueki J; Gon Y; Seki T; Anzai T; Nakamura S; Hirata K
    Int J Chron Obstruct Pulmon Dis; 2018; 13():1407-1419. PubMed ID: 29750027
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of Tiotropium/Olodaterol Compared with Tiotropium as a First-Line Maintenance Treatment in Patients with COPD Who Are Naïve to LAMA, LABA and ICS: Pooled Analysis of Four Clinical Trials.
    Buhl R; de la Hoz A; Xue W; Singh D; Ferguson GT
    Adv Ther; 2020 Oct; 37(10):4175-4189. PubMed ID: 32671684
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The efficacy and safety of combined tiotropium and olodaterol via the Respimat(®) inhaler in patients with COPD: results from the Japanese sub-population of the Tonado(®) studies.
    Ichinose M; Taniguchi H; Takizawa A; Grönke L; Loaiza L; Voß F; Zhao Y; Fukuchi Y
    Int J Chron Obstruct Pulmon Dis; 2016; 11():2017-27. PubMed ID: 27621608
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tiotropium/Olodaterol Delays Clinically Important Deterioration Compared with Tiotropium Monotherapy in Patients with Early COPD: a Post Hoc Analysis of the TONADO
    Rabe KF; Chalmers JD; Miravitlles M; Kocks JWH; Tsiligianni I; de la Hoz A; Xue W; Singh D; Ferguson GT; Wedzicha J
    Adv Ther; 2021 Jan; 38(1):579-593. PubMed ID: 33175291
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of tiotropium and olodaterol on symptoms and patient-reported outcomes in patients with COPD: results from four randomised, double-blind studies.
    Ferguson GT; Karpel J; Bennett N; Clerisme-Beaty E; Grönke L; Voß F; Buhl R
    NPJ Prim Care Respir Med; 2017 Feb; 27(1):7. PubMed ID: 28154373
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Costs, exacerbations and pneumonia after initiating combination tiotropium olodaterol versus triple therapy for chronic obstructive pulmonary disease.
    Palli SR; Buikema AR; DuCharme M; Frazer M; Kaila S; Juday T
    J Comp Eff Res; 2019 Nov; 8(15):1299-1316. PubMed ID: 31559852
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 32.